TriSalus Life Sciences Warrant
TLSIW
23 hedge funds and large institutions have $160K invested in TriSalus Life Sciences Warrant in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
50,200% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $3K
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
4% less funds holding
Funds holding: 24 → 23 (-1)
33% less capital invested
Capital invested by funds: $238K → $160K (-$77.8K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| 1 |
ETH
Exos TFP Holdings
New York
|
+$10.7K |
| 2 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$4.22K |
| 3 |
FTUS
Flow Traders U.S.
New York
|
+$465 |
| 4 |
HF
HRT Financial
New York
|
+$7 |
Top Sellers
TLSIW Hedge Fund Activity: Q2 2023 in Review
23 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences Warrant (TLSIW) for Q2 2023, worth a combined $160K — down 33% from $238K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TLSIW and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 4 added.
The largest buyer was Exos TFP Holdings, adding an estimated $10.7K. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $7.59K sold.
- 23 institutional investors held TriSalus Life Sciences Warrant (TLSIW) as of Q2 2023, down from 24 in Q1 2023.
- Funds reported $160K of TriSalus Life Sciences Warrant stock for Q2 2023, down 33% quarter-over-quarter.
- 2 funds opened new TriSalus Life Sciences Warrant positions in Q2 2023 and 3 closed out, a net change of -1 holder.
- The largest TriSalus Life Sciences Warrant buyer in Q2 2023 was Exos TFP Holdings, an estimated $10.7K added.
- The largest TriSalus Life Sciences Warrant seller in Q2 2023 was Balyasny Asset Management, an estimated $7.59K sold.
Based on aggregated 13F filings for Q2 2023.